Research contract
Party A: Eternal Technology Group Limited
Party B: Towering International Trad (US) Corp
Both parties agree on the research and development as below:
1. Project aim
1.1 Background
Thrombosis diseases are with high death probability. In China, there
are over 10,000,000 cases of death relating to Thrombosis per annum.
The common curing method are........However, these methods have
side-effects like......From research, it is found that Thrombin-like
enzymes from snake venom can convert fibrinogen into fibrin. The
research has extended to more species of snake venom. 1.2 Details The
extracts from venom of Chinese Agkistrodon Halys is.....This venom
protein has been approved by the Department of Health of China......The
research has successfully processed purification and extraction of
snake venom by......
1.3 Major research area and stages
Party A agree to invest in the research project and both parties agrees
as follows: Stage I Party purchases the gene cloning result of venom of
Chinese Agkistrodon Halys from Party B Party A agree to pay
US$1,400,000 in total
Payment method: US$200,000 on January 2001
Party B's consideration: gene cloning result of venom Chinese
Agkistrodon Halys Stage II Upon completion of gene cloning of venom of
Chinese Agkistrodon Halys, proceeds to utilization of the gene cloning
on other living creature....production of relevant products. First
payment: Upon completion of gene cloning, Party A pay US$400,000 in
July 2002 Second payment: Upon utilization of the gene cloning on other
living creature, Party A pay US$400,000 in September, 2002 Third
payment: Upon application of sole right, Party A pay US$400,000 in
December 2002 Warranty: Party B guarantee to complete the research and
obtain the sole right within 2002.
Party A: signed
Party B: signed
Dated: 6th January, 2001
Acknowledgment of receipt
Eternal Technology Group Limited
We acknowledgment receipt of cash up to 30th June, 2002 in respect of
genetic cloning of thrombin like enzyme from snake venom amounted to
US$400,000.
Signed: Tower International Trad(US) Corp
Dated 30th June, 2002
Research contract
Party A: Eternal Technology Group Limited
Party B: Shen Yang Institute of Applied Ecology of Chinese Academy of
Science
Both parties agrees as follows:
1. Project aim
1.1~ Cancers are one of the major cause of death
[Brief introduction of cancer]
1.2 Staphylococcal Enterotoxin is superantigen
[Description of superantigen and how it cure cancer]
1.3 Staphylococcal Enterotoxin as antitumor drug
[Historical development of staphylococcal Enterotoxin, statistics]
1.4 Development of first priority drug
[National encouragement policy on development of drugs for cancer]
2. Development of technology and markets
2.1 Enteroxin has been used in China in the past ten years
with satisfactory results 2.2 Development status of Enteroxin
in foreign country 2.3 Antitumor drugs and Local and Overseas
markets
3. Major theme of research and stage proposal 3.1 Stage I
3.1.1 Aim: The construction and cloning of superantigen staphylococcal
exterotoxin B and separation technology development
3.1.2 Duration: three years
3.1.3 Details
3.1.3.1 Grow of high quality staphylococcal extertoxin B
3.1.3.2 Research and analysis of staphylococcal extertoxin B
3.1.3.3 Construction of staphylococcal exterotoxin B
3.1.3.4 Modification of DNA
3.1.3.5 Improvement of growing method of staphylococcal extertoxin B
3.1.3.6 Development of separation and purification method for drugs materials
3.1.4 Target result of stage I
3.1.4.1.Application of right and the sole right belong to Party A
3.1.4.2.Complete construction of DNA of drug
3.1.4.3.Complete purification work and the standard should meet the
National Drug standard
3.1.4.4.Test of DNA drug
3.2. Stage II
3.2.1. Aim Research gargeting on antitumor medicine
3.2.2. Duration: (Base on the result of stage one, an additional one year)
total of 4 years
3.2.3. Details: Target on antitumor medicine...production of antitumor medicine
3.3.4. Target and projected result
3.3.4.1.Application of sole right
3.3.4.2.Complete test of medicine
4. Funds
4.1. First year US$300,000
4.2. Second year US$300,000
4.3. Third year US$300,000
4.4. Forth year US$300,000
5. Payment terms: Settlement in full each year no later that 31 July.
Party A: signed
Party B: signed
Dated 27th February 2001
Acknowledgment of receipt
Eternal Technology Group Limited
We acknowledge receipt of cash up to 30th June, 2002 in relation to
research work on targeting antitumor Drug amounted to US$600,000
Signed: Shen Yang Institute of Applied Ecology of Chinese Academy of
Science.
